Inhibitor Therapeutics (INTI) Accumulated Expenses (2014 - 2026)
Inhibitor Therapeutics' Accumulated Expenses was $9,580 in Q2 2026, up 24.0% from $7,725 a year earlier but down 71.4% from the prior quarter.
Powered by 
Analysis
Inhibitor Therapeutics (INTI) Accumulated Expenses (2014 - 2026) Analysis & Trends
At the end of FY2025, Accumulated Expenses at Inhibitor Therapeutics came in at $690,085, down 0.5% from FY2024.
- Accumulated Expenses shows a four-year compound annual growth rate of 90.0% (FY2021 to FY2025).
- In earlier years, Accumulated Expenses was $693,722 in FY2024 (+9.9%), $631,433 in FY2023 (+414.9%), $122,621 in FY2022 (+131.4%) and $53,000 in FY2021.
- Quarterly Accumulated Expenses has moved between $7,725 (Q2 2025) and $693,722 (Q4 2024) over five years.
- Compared with a year earlier, Accumulated Expenses was higher in three of the last eight quarters, with an average decline of 10.1%.
- The best year-over-year quarter for Accumulated Expenses over five years was Q4 2023 (growth of 414.9%); the worst was Q2 2025 (a decline of 53.8%).
- Per Business Quant data, INTI's Accumulated Expenses in the three quarters before Q2 2026 was $33,536 (Q1 2026), $690,085 (Q4 2025) and $40,432 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Inhibitor Therapeutics | 17.38 Mn | 17.38 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9,580.00 |
| Mar 31, 2026 | 33,536.00 |
| Dec 31, 2025 | 690,085.00 |
| Sep 30, 2025 | 40,432.00 |
| Jun 30, 2025 | 7,725.00 |
| Mar 31, 2025 | 32,023.00 |
| Dec 31, 2024 | 693,722.00 |
| Sep 30, 2024 | 42,853.00 |
| Jun 30, 2024 | 16,724.00 |
| Mar 31, 2024 | 43,934.00 |
| Dec 31, 2023 | 631,433.00 |
| Sep 30, 2023 | 63,293.00 |
| Jun 30, 2023 | 32,109.00 |
| Mar 31, 2023 | 73,436.00 |
| Dec 31, 2022 | 122,621.00 |
| Dec 31, 2021 | 53,000.00 |
| Jun 30, 2015 | 103,000.00 |
| Dec 31, 2014 | 23,000.00 |
API Access
Inhibitor Therapeutics Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "accumulated-expenses", "ticker": "INTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=INTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();